Calcitonin gene-related peptide monoclonal antibody
Calcitonin gene-related peptide monoclonal antibodies (mAbs) or CGRP mAbs are a new type of preventative migraine treatment. CGRP mAbs block the release of calcitonin gene-related peptide, a neurotransmitter known to cause migraines.
Drugs[edit | edit source]
Currently FDA-licensed CGRP mAbs are:
- Eptinezumab (Vyepti), approved in 2020
- Erenumab (Aimovig), approved in 2018
- Fremanezumab (Ajovy), approved in 2018
- Galcanezumab (Emgality), approved in 2018
Uses[edit | edit source]
News and articles[edit | edit source]
- 2020, Can migraines be untangled by new medical thinking? - The Observer
Learn more[edit | edit source]
- Calcitonin gene-related peptide monoclonal antibodies - The Migraine Trust
- CGRP Medications - Migraine Australia
See also[edit | edit source]
References[edit | edit source]
- "Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies". The Migraine Trust. Retrieved October 12, 2021.
- "What are the new drugs for the treatment of migraines?". Drugs.com. Retrieved October 12, 2021.
- Negro, Andrea; Martelletti, Paolo (June 2019). "Gepants for the treatment of migraine". Expert Opinion on Investigational Drugs. 28 (6): 555–567. doi:10.1080/13543784.2019.1618830. ISSN 1744-7658. PMID 31081399.
- Kang, Seung Ah; Govindarajan, Raghav (2021). "Anti-calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache". Muscle & Nerve. 63 (4): 563–567. doi:10.1002/mus.27153. ISSN 1097-4598.